Enanta Pharmaceuticals Inc (ENTA) Quote

Yeah for a study that most think will be positive I too am starting to think they may have a miss or at least some mixed data. We will probably know more in the coming days w their earnings
The long Covid endpoints are at 24 weeks in the trial listing but they said more than once they plan to unblind data at 12 weeks so??

“we have completed the enrollment of over 2,000 cases in December 2023. For the primary endpoint, the time to resolution of all COVID-19-related symptoms, all 15 symptoms, was determined after consultation with the FDA. In addition, we have obtained data on the suppression of the incidence of Long COVID, so-called sequelae, at 12 weeks, and we are verifying this as well in SCORPIO-HR trial. We are keeping the data up to three months under blind, so we expect to be able to present our results to you in April on these results as a topline after a three-month follow-up starting in December.”

April came and went with no PR. You would think an outright hit or miss would be a straightforward readout so perhaps they are doing some post hoc data mining? Could also be they decided to keep the trial blinded out to 24 weeks who knows

dewophile, thanks for the link and the comments. My take is that they missed the primary end point and are on the edge of the long-Covid data so are extending the trial to see if they can at least hit the reduction in the incidence of long Covid.

I think as you and DewDiligence posted, that the $3 billion number for Paxlovid sales is providing a boost to ENTA so that EDP-235 may have some value after all.

I concur that Paxlovid 1Q24 sales and 2024 guidance are not surprising; however, I think some investors were confused by PFE's 4Q23 writeoff and didn't realize that the 2023 figure was an accounting artifact rather than a reflection of product demand.

Not sure but I wasn’t surprised by paxlovid sales and think they are lowballing guidance still. They are still the only game in town in western countries although most people think ensitrelvir will be on the market here by early 2025 (although the odds went down a bit IMO when they missed their own guidance for reporting top line data)

Is ENTA getting a delayed bounce from PFE’s $3B 2024 sales guidance for Paxlovid?

This is what Shionogi said on their call Jan 31:

https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2023/3q/e20240202.pdf

“we have completed the enrollment of over 2,000 cases in December 2023. For the primary endpoint, the time to resolution of all COVID-19-related symptoms, all 15 symptoms, was determined after consultation with the FDA.
In addition, we have obtained data on the suppression of the incidence of Long COVID, so-called sequelae, at 12 weeks, and we are verifying this as well in SCORPIO-HR trial. We are keeping the data up to three months under blind, so we expect to be able to present our results to you in April on these results as a topline after a three-month follow-up starting in December.”

April came and went with no PR. You would think an outright hit or miss would be a straightforward readout so perhaps they are doing some post hoc data mining? Could also be they decided to keep the trial blinded out to 24 weeks who knows

Latest Patents Assigned to Enanta Pharmaceuticals, Inc.

Macrocyclic antiviral agents
Patent number: 11970502
Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 30, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Patent number: 11958879
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Enanta Pharmaceuticals (from X)

Our team presented “Efficacy and Safety of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study” at
@ESCMID Global where it was named a “Top Rated Poster.” Congratulations to the team.

POSTER CONCLUSIONS
• EDP-235 treatment in standard-risk adults with mild or moderate COVID-19 yielded a favorable safety profile and improvements in clinical symptoms
• EDP-235 was generally well tolerated, as reflected by a low frequency of TEAEs that were mostly mild in severity, and there were no serious TEAEs or
TEAE-related discontinuations
• The 400 mg dose of EDP-235 achieved statistically significant improvement in TSS at multiple time points in the overall study population
– In participants enrolled within 3 days of symptom onset, along with significant TSS improvement at all time points, a median 2-day shorter
duration of 6 selected COVID-19 symptoms was observed
• The rapid decline of viral load across all study groups was consistent with an enrolled population that had prior immunity
• The results of the Phase 2 SPRINT study support further development of EDP-235 for the treatment of COVID-19
• As the therapeutic target is conserved across variants, EDP-235 may prove an effective tool to combat future variants of SAR-CoV-2 and potentially
other coronaviruses

Read more:
https://www.enanta.com/wp-content/uploads/2024/04/P0423_ECCMID_2024_SPRINT_Poster_FINAL.pdf

I think maintaining continuity of in-house general counsel would be important during the on-going patent litigation. I also think the experience attained during the term with Enanta would be beneficial to retain during negotiations for Enanta's various technologies -- outsourcing, partnering.

As Dewophile said, neither ENTA nor PFE uses in house lawyers to argue the case, so it is a non-issue.

I think maintaining continuity of in-house general counsel would be important during the on-going patent litigation. I also think the experience attained during the term with Enanta would be beneficial to retain during negotiations for Enanta's various technologies -- outsourcing, partnering.

I am quite reasonable and I consider this an untimely and likely disruptive loss which is worthy of acknowledgement thru mention on this board.

Nathaniel Gardiner retired at what could be considered the pinnacle of his career with Enanta, during a high profile lawsuit with Pfizer? Who is your clown?

So do you think he ran away because ENTA might lose the case and he couldn't bear the embarrassment? Do you think the patents and patent violation claims themselves have no bearing, and all that matters is who is doing the arguing?

The case is farmed out to a high profile MA based firm. The in house counsel is not actively managing the case at all
Even Pfizer uses outside counsel to manage a case like this which requires specific expertise which they simply don't keep in house

Gardiner is 71. I don't see anything odd about his retirement.

Nathaniel Gardiner retired at what could be considered the pinnacle of his career with Enanta, during a high profile lawsuit with Pfizer? Who is your clown?

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
Apr 30, 2024

“I’m pleased to welcome Matt to Enanta. The breadth of his legal expertise across a wide range of activities in the life sciences industry, including his experience with early and late-stage clinical trials, commercial products, intellectual property, business development and other corporate transactions, makes him an important addition to the Enanta leadership team as we advance toward several important catalysts this year,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “In addition to his strong expertise and experience, Matt is a proven leader in life sciences, which will support our continued growth as we further our mission of developing important medicines in virology and immunology.”

“I’m proud to join a team with an established track record of success, dedicated to the discovery and development of groundbreaking small molecule drugs in areas of significant unmet medical need,” said Matthew Kowalsky. “With multiple near-term catalysts across the pipeline and a solid cash position, this is an important and transformational time for Enanta. I look forward to collaborating with the seasoned management team to support all initiatives aimed at progressing our pipeline, improving the lives of patients and their caregivers, and enhancing shareholder value.”

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-appointment-matthew-p-kowalsky

Furthermore -

the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its common stock, performance share units (PSUs) for 4,468 shares of its common stock, and relative total stockholder return units (rTSRUs) for 4,468 shares of its common stock, under the company’s 2024 Inducement Stock Incentive Plan.

The 2024 Inducement Stock Incentive Plan has been adopted by the Board of Directors to be used exclusively for the grant of equity awards to any individual who was not previously an employee or non-employee director of Enanta Pharmaceuticals, as an inducement material to such individual's entering into employment with Enanta Pharmaceuticals, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Read more:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-inducement-grants-under-nasdaq

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
Apr 29, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-host-conference-call-may-6-430-pm-et

Media recognition & coverage -

Pharmaceutical Technology -
April 22

Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula
Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (I) represents the compound structure.

Excerpts:
Human telomerase RT biomarker was a key innovation area identified from patents.

The patent also covers pharmaceutical compositions containing the compound and a method for treating or preventing coronavirus infections in subjects by administering the compound or a combination of compounds.

....the patent involves administering a therapeutically effective amount of the compound to subjects in need, with specific mention of various types of coronaviruses, including SARS-CoV-2. This patent highlights the potential use of the disclosed compounds in combating coronavirus infections, particularly relevant in the current global health scenario.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i-2/?utm_source=lgp6-patents-grant&utm_medium=24-295866&utm_campaign=recommended-articles-pi&cf-view

I never considered a data leak on the RSV drug, but there could be a leak on ensitrelvir data (run by NIH and they have data in hand so could be more leaky than if was strictly managed by shionogi I think) or some happenings in the court case. Most likely of course is that the recent drop is just due to inherent volatility

Right! ENTA updated the guidance for RSVHR reporting on the Leerink webcast on 3/13/24 (the same date as the “new” corporate slide set). The prior “it depends” guidance was from ENTA’s FY1Q24 CC on 2/7/24.

In any event, the salient point is that ENTA is not due to report any clinical data until July at the earliest. This should reassure anyone who may have thought the recent share-price decline was due to a data leak.

ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.

ENTA mentioned that they will have to go to the southern hemisphere for the RSVHR study so enrollment won't be completed for this study in the 2024 northern hemisphere season, but could still be completed this calendar year after the southern hemisphere season
I don't recall if ENTA had as much detail on the CSU program, but they did mention during the last presentation they have been working on it for a long time (over a year), so I am hoping they are not too far behind THRD (which incidentally has a higher valuation w their CSU program being the lone asset and cash through 2026 vs 2027 for ENTA)

ENTA corporate slide set (3/13/24):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

There are no differences between the 3/13/24 slide set and the previous slide set on 2/7/24.

Clinical newsflow reiteration: ENTA expects to report data from the Zelicapavir RSVPEDs trial and the EDP-938 “challenge” trial in 3Q24. ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.

Just calling it the way I see it - ENTA does have a potential stake in paxlovid
PFE has been totally silent on their next gen PI for covid - the phase 2 was completed months ago

https://clinicaltrials.gov/study/NCT05799495?term=PF-07817883&rank=5

Regardless negative ensitrelvir data would still be bullish for ENTA because it is bullish for paxlovid which would make any potential settlement in the lawsuit more valuable (and vice versa of course if the ensitrelvir data are good)

I like the way you talk! 😂

The market is upset they are allocating the cost of a plane ticket to Spain and hotel for the presentation. It's a few thousand added burn ;)
Joking aside nice to see the data will be presented - it's the right thing to do even on what seems to be a defunct asset
235 could be revived if ensitrelvir doesn't post positive phase 3 data this month. Regardless negative ensitrelvir data would still be bullish for ENTA because it is bullish for paxlovid which would make any potential settlement in the lawsuit more valuable (and vice versa of course if the ensitrelvir data are good)

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

No wonder ENTA dropped yesterday and today. It is a reminder that EDP-235 still hasn't moved into phase 3 despite excellent data in phase 2, either via partnership or funded by ENTA.

Capisce?

Everything makes CENTS in a potential takeover. I consider the patent holdings are worth their minimal expense - I.E. the patent infringement suit against PFIZER - if it pans out.

Legal Fees for Patent Applications and Patent Defense
The 8-K shows that patent defense legal fees are assigned to General and Administrative Expenses. Are patent application fees assigned to research and development costs? For years I thought Enanta's patent portfolio was a wonderful asset, but now I am wondering if it was an unscrupulous waste of money transferring oodles of cash from Enanta to their legal counsel. Kickback and enjoy. Capisce?

Patent Assigned to Enanta Pharmaceuticals, Inc.

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

In certain embodiments, the FXR-mediated disease or condition is cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesteremia, or hyperlipidemia chronic liver disease, gastrointestinal disease, renal disease, metabolic disease, cancer (i.e., colorectal cancer), or neurological indications such as stroke.

https://patents.justia.com/patent/11958879

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-data-presentation-escmid-global

one must be able to describe the thinking and process one takes to create that molecule- if one is to defend their IP.

Thanks for your comments re:patents. Seems ENTA is flush with patents protecting their small molecule discoveries. It would make "cents" to have their discoveries certified & protected by their string of patent attorneys. **Pfizer - watch out!

**

I rather enjoy the updates on Enanta's being issued patents.
I long for the day that these will mean something palpable in it's share price.

I hold (or is it merely wishful thinking?) that a company that is centered on discovering molecules MUST have a branch that can rigorously defend those patents, that's skilled at filing patents. It isn't enough to merely create them after, one must be able to describe the thinking and process one takes to create that molecule- if one is to defend their IP.

I say this as Enanta's lawsuit progresses with Pfizer and hope that they have done the work required to successfully defend their IP.

They keep comin' !

Patents Assigned to Enanta Pharmaceuticals, Inc.
** Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024

Patents Assigned to Enanta Pharmaceuticals, Inc.
Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
Assignee: Enanta Pharmaceuticals, Inc.

** What are Benzodiazepines? Benzodiazepines are depressants that produce sedation and hypnosis, relieve anxiety and muscle spasms, and reduce seizures. The most common benzodiazepines are the prescription drugs Valium®, Xanax®, Halcion®, Ativan®, and Klonopin®.

2 New Patents Assigned to Enanta Pharmaceuticals, Inc. as of April 2

Heterocyclic compounds as anti-viral agents
Patent number: 11945824
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: October 18, 2021
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

Taking account of the seasonality and predictability of the HRSV and HMPV epidemics, and the severity of infection in high-risk groups such as infants, immunocompromised patients and adults over the age of 65 years, the need for a potent and effective treatment for both HRSV and HMPV is clear. The present invention has identified heterocyclic compounds that are potent inhibitors of both HRSV-A/B and HMPV. The invention includes methods to prepare these compounds, methods for RSV/HMPV cell-based assays and methods of using these compounds to treat HRSV and/or HMPV infections.

https://patents.justia.com/patent/11945824

Antiviral heterocyclic compounds
Patent number: 11945830
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: February 24, 2022
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

The present invention has identified compounds that are heterocyclic molecules that are potent against HRSV-AB and HMPV. The invention includes methods to prepare these molecules, methods for the RSV cell-based assay, the HMPV-GFP cell-based assay, the HMPV-TN/1501/A1 cell-based assay, and small-molecules that have potential to treat HRSV/HMPV infection.

https://patents.justia.com/patent/11945830

What is heterocyclic used for?
Heterocyclic Compound - an overview | ScienceDirect Topics
The heterocyclic compounds play an important role in regulating the biochemical process in living system. The compounds may be genetic material, hormones, and enzymes. The common heterocyclic compounds that serve as potential leading drug candidates include amino acid, vitamins, and coenzymes.

https://endpts.com/loosening-medicaid-restrictions-on-hep-c-drugs-could-improve-patient-access-study-finds/

ENTA over $10

PHARMACEUTICAL TECHNOLOGY research news via GlobalData -

March 29, 2024
Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I).

Excerpts:
Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus.

The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i/

As impressive as this rise in ENTA stock price over this week (from $14 to $17.41), its market cap is still only $370 million. That means any solid positive news could drive a major price spike.

Not sure. Wish I have more money here than that damn RVNC. lol

I hesitate to post this but I'm going to include a link, a chart.
https://finviz.com/quote.ashx?t=ENTA&p=d
We've been in an uptrend and when I see a huge spike, or series of large spikes they are often followed by a selloff.
How well I know that lesson. : (

Maybe Enta will go up, and up.
BUT particularly if this is just a large day or a series of large days anyone just (or pondering) getting in should realize that someone is going to take profits.
IE, runups are often precursors to selloffs.

Since my broker had NO idea - I did some research to prevent my brokerage firm from "borrowing" my ENTA shares for any short sales.

How do I stop short sellers from borrowing my shares?
All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today's price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes.

You aren't alone there.
I've been following and looking an a longer chart and it looked like a semi legit uptrend and so I bought in right at the top near $16.00 and it promptly went back to the basement. That must have been a few weeks ago.
I've got a knack that way. : )
Hey, IF I'm going to go down, I might as well go down in flames. : )
I'm feeling 10 percent smarter today but still in the red from last purchase.

What the heck is going on with ENTA today? Up more than 10% on no news. Could it be a leak about the lawsuit against PFE? Maybe not as the volume isn't particularly high.

As a new, approximately 6 month investor in ENTA, I appreciate the correction. Live & learn - thanks Dew

No. ENTA's lawsuit against PFE concerns protease inhibitors for SARS-CoV-2; it has nothing to with RSV.

Might the following new patent be valid for inclusion in the PFIZER suit?

COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS
File Date: .................... 2018-09-28.
Pub Date: .....................2024-03-20

Excerpts:

Background of the Invention:
RSV is the leading cause of acute lower respiratory tract infections (ALRI) and affects patients of all ages. The symptoms in adults are usually not severe and are typically analogous to a mild cold. However, in infants and toddlers the virus can cause lower respiratory tract infections including bronchiolitis or pneumonia with many of them requiring hospitalization. Nearly all children have been infected by age 3. There are known high-risk groups that infection with RSV is more likely to progress into the ALRI. Premature infants and/or infants suffering from lung or cardiac disease are at the highest risk to develop ALRI. Additional high-risk groups include the elderly, adults with chronic heart and/or lung disease, stem cell transplant patients and the immunosuppressed.

DETAILED DESCRIPTION OF THE INVENTION:
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.

Read more:
https://www.patentguru.com/EP3687543B1



.

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease - March 12

Enanta Pharmaceuticals. has filed a patent for compounds of Formula (I) as 17ß-HSD13 inhibitors for treating metabolic diseases** and liver conditions. The patent claim includes a compound represented by Formula I or its pharmaceutically acceptable salt or ester.

Furthermore, the patent application describes methods for preventing or treating 17ß-HSD13 mediated diseases or conditions in individuals by administering a therapeutically effective amount of the compound. The diseases or conditions targeted include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC). The use of the compound in the manufacture of medicaments for these specific diseases is also claimed, emphasizing the potential therapeutic applications of the disclosed compound.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-files-patent-for-17-hsd13-inhibitors-for-treating-metabolic-disease/

**Metabolic disorders: Types, causes, and symptoms -
Examples of metabolic disorders include diabetes, Gaucher's disease, and hemochromatosis. Symptoms can include tiredness, weight loss or gain, and nausea and vomiting. Metabolism is a term that describes the biochemical processes that allow people to grow, reproduce, repair damage, and respond to their environment.

Thank you.

Is this how Amgen started out?

Everything you wanted to know about ENANTA's Patents -

Enanta Pharmaceuticals Patents – Key Insights and Stats
October 25, 2023

Enanta Pharmaceuticals has a total of 1607 patents globally, out of which 619 have been granted. Of these 1607 patents, more than 49% patents are active.

Read more:
https://insights.greyb.com/enanta-pharmaceuticals-patents/

I’m not saying that Hepludex infringes ENTA’s new HDV patent, but for the sake of discussion let’s assume that it does.

I see what you are saying.

Is this how Amgen started out? Was there a huge patent collection, but much difficulty in establishing collaborations and getting their products into the market? At nearly two decades Enanta must be getting close to their breakout, next Amgen.